"Mountain River Pharmaceutical Assistance: Fosun Pharma reduced its holding of the company's shares by 0.98%"

Shanhe Pharmaceutical announced that its shareholder Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., which holds more than 5% of the shares, plans to reduce its holdings by a total of no more than 6,978,000 shares (3% of the total share capital) through centralized bidding and block trading from March 18, 2025 to June 15, 2025. Recently, the company received a notification from Fosun Pharmaceutical regarding the completion of the share reduction plan. The reduction plan was completed on June 15, 2025, with an average reduction price of 12.54 yuan per share, reducing the number of shares by 2.2828 million (0.98%). After the reduction, Fosun Pharmaceutical holds 21.6453 million shares, accounting for 9.23% of the total share capital. The reduction plan did not violate any laws or regulations, and the company's production and operation are normal, with no change in control.